All In Biotech

Drug Trial Radar · NCT02712203

MMR and MMRV Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.

Measles-mumps-rubella and Measles-mumps-rubella-varicella Vaccines: Effect of Age at First Dose on Safety and Immunogenicity of the Measles Component.

Last checked: Nov 20, 2026Latest source record: Mar 18, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

5,808

Actual

Start

Jul 2004

Primary completion

Jul 2010

Study completion Dec 2016

Sponsor

Lead sponsor
CHU de Quebec-Universite LavalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
GlaxoSmithKline
First posted
Mar 18, 2016

More drug trials from this sponsor

Design

Study type
Observational
Who can join
All sexes, from 11 months, up to 22 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Healthy children who received two doses of GlaxoSmithKline (GSK) Biologicals' live attenuated measles-mumps-rubella vaccine (MMR) or measles-mumps-rubella-varicella vaccine (MMRV) in their second year of life.The purpose of this study is to assess the effect of the age at administration of the first dose on the reactogenicity and immunogenicity of the measles component of these vaccines. In addition, this study will evaluate if the effect of the age at first dose is modified by the type of vaccine administered.

Conditions

  • Measles

Interventions

  • MMR vaccine / MMRV vaccineBiological

    Subcutaneous injection, two doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Short term seropositivity rates & anti-measles antibody titers after vaccination with MMR or MMRVTime frame: At day 42 after administration of a dose of MMR or MMRV vaccine

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.